Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

XADAGO 50 MG COMPRIMIDOS RECUBIERTOS CON PELICULA - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/XADAGO 50 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

Approved

STANDARD

XADAGO 50 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

Zambon S.P.A.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jun 6, 2023
Approval ID: 2d4a27f396f95023
Company: Zambon S.P.A.
Type: Standard

Approval Details

Approval Id: 2d4a27f396f95023
Drug Cima Aemps Name: XADAGO 50 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
Register Number: 114984003IP3
Holder Company Name: Zambon S.P.A.
Marketing Company Name: Elam Pharma Labs S.L.
Authorization Date: 2023-06-06
Dosage Form: COMPRIMIDO RECUBIERTO CON PELÍCULA
Dose: 50 MG
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Zambon S.P.A.

Active Ingredients

SAFINAMIDA

50 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jun 6, 2023

Approval ID

2d4a27f396f95023

Type

Standard

Back to CIMA-AEMPS Approvals